A Phase 1 Study of VK3019 in Overweight and Obese Adults Without Comorbidities

Conditions

• Obese Adults

Eligibility Criteria

Sex

ALL

Age

18 Years - 60 Years

Healthy Volunteers

Not accepted

Interventions

• SC VK3019 — DRUG
  Single dose VK3019
• Matching placebo — DRUG
  Single dose matching placebo

Study Details

This is a Phase 1, randomized, double-blind, placebo-controlled single ascending dose (SAD) study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of VK3019 in overweight and obese adults without comorbidities.

Key Dates

First listed

Sep 29, 2026

Start date

Jul 6, 2026

Status verified

Sep 2026

Primary completion

Oct 2, 2026

Completion

Nov 30, 2026

Study Design

Enrollment

56 participants (estimated)

Allocation

RANDOMIZED

Intervention model

SEQUENTIAL

Primary purpose

TREATMENT

Arms

• Experimental: VK3019 Dose Level 1
  Single-dose VK3019 or placebo administered subcutaneously
• Experimental: VK3019 Dose Level 2
  Single-dose VK3019 or placebo administered subcutaneously
• Experimental: VK3019 Dose Level 3
  Single-dose VK3019 or placebo administered subcutaneously
• Experimental: VK3019 Dose Level 4
  Single-dose VK3019 or placebo administered subcutaneously
• Experimental: VK3019 Dose Level 5
  Single-dose VK3019 or placebo administered subcutaneously
• Experimental: VK 3019 Dose Level 6
  Single-dose VK3019 or placebo administered subcutaneously
• Experimental: VK3019 Dose Level 7
  Single-dose VK3019 or placebo administered subcutaneously

Primary Outcome Measure

Evaluate the safety of single doses of subcutaneous administration of VK3019 [ Time Frame: 36 days ]

Central Contacts

• Hubert C Chen, MD
  8587044660
  [email protected]

Locations (1)

Find similar trials in Lake Forest, CA

Related Studies

• A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities
  PHASE1 · Recruiting · Viking Therapeutics, Inc. · Lake Forest, California